• Regorafenib (BAY 73-4506): Applied Workflows in Cancer Biolo

  2026-06-18

  Regorafenib (BAY 73-4506) stands out as a potent multikinase inhibitor, empowering researchers to dissect angiogenic and oncogenic pathways in both in vitro and in vivo cancer models. This guide translates the latest mechanistic breakthroughs and experimental optimizations into actionable protocols, troubleshooting insights, and workflow enhancements for advanced cancer biology research.

• Trichostatin A (TSA): Precision Epigenetic Modulation in Can

  2026-06-17

  Trichostatin A (TSA) from APExBIO is a gold-standard HDAC inhibitor, enabling targeted epigenetic regulation and robust cell cycle control in cancer models. This article details advanced workflows, troubleshooting insights, and cross-domain applications that leverage TSA’s unique mechanistic profile for high-impact oncology and immunology research.

• Propidium Iodide: DNA Intercalating Dye for Cell Viability S

  2026-06-17

  Propidium iodide is a robust DNA intercalating dye widely used for distinguishing viable from non-viable cells due to its membrane-impermeant properties. It enables precise cell viability assays, apoptosis detection, and cell cycle analysis in basic and translational research. APExBIO’s B7758 formulation ensures high experimental reproducibility and specificity in cytometric workflows.

• Calcitriol: Mechanistic Depth and Translational Impact in En

  2026-06-16

  Explore how Calcitriol, the active metabolite of vitamin D3, orchestrates endometrial decidualization and immune modulation through vitamin D receptor signaling. This in-depth analysis uncovers novel mechanistic insights and practical assay guidance for advanced research.

• Bile Acid Metabolism Subtyping Reveals CRC Prognostic Marker

  2026-06-16

  Feng et al. (2026) establish a molecular subtyping framework for colorectal cancer (CRC) based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as key markers of immune dysfunction and poor prognosis. This integrative approach enhances understanding of the tumor immune microenvironment and supports improved patient stratification for future biomarker-driven research.

• SR-202: Applied Workflows for PPARγ Antagonism in Metabolic

  2026-06-15

  SR-202 enables precise, selective modulation of PPARγ-driven pathways in metabolic and immunological models. Its robust workflow compatibility, high solubility, and targeted antagonism make it an essential tool for dissecting insulin resistance mechanisms and anti-obesity drug development.

• Afatinib (BIBW 2992): Irreversible ErbB Kinase Inhibitor in

  2026-06-15

  Afatinib is a covalent, irreversible tyrosine kinase inhibitor that targets EGFR, HER2, and HER4, making it a key tool in cancer biology research. Its efficacy in overcoming resistance mechanisms, particularly in advanced gastric cancer assembloid models, is well-supported by recent preclinical evidence. APExBIO supplies Afatinib (A4746) at research grade purity for non-clinical use.

• GRA12 Identified as a Universal Toxoplasma gondii Virulence

  2026-06-14

  This study presents a systematic in vivo CRISPR screen revealing GRA12 as a key secreted virulence factor in Toxoplasma gondii, conserved across parasite lineages and mouse subspecies. The findings illuminate new aspects of parasite immune evasion and offer broad implications for host-pathogen interaction research.

• Applied Cancer Research with LEE011 Succinate: CDK Inhibitor

  2026-06-13

  Ribociclib succinate (LEE011 succinate) delivers highly selective CDK4/6 inhibition, enabling precise cell cycle arrest in HER2-positive breast cancer research and beyond. This guide details advanced protocols, troubleshooting essentials, and data-driven insights to optimize cancer research workflows using this antineoplastic agent.

• Synthetic Viability with ERCC1 Deficiency in Lung Cancer: Me

  2026-06-12

  This article analyzes a landmark study that reveals how p53 status modulates synthetic viability and DNA repair pathways in ERCC1-deficient lung cancer cells following interstrand crosslink (ICL) damage. The findings highlight the importance of genetic context in predicting platinum chemotherapy responses and inform future strategies for exploiting DNA repair vulnerabilities in cancer.

• BMN 673 (Talazoparib): Precision Tool for DNA Repair Deficie

  2026-06-12

  BMN 673 (Talazoparib) stands apart as a next-generation, ultra-potent PARP1/2 inhibitor, enabling selective targeting of homologous recombination deficient cancer models. Its unique PARP-DNA complex trapping and synergy with DNA-damaging agents empower advanced assay workflows and translational research, with APExBIO ensuring reliable access for experimental reproducibility.

• A20 Modulates Oxidized Self-DNA Inflammation in Acute Kidney

  2026-06-11

  The referenced study elucidates how the ubiquitin-editing enzyme A20 mitigates inflammation in acute kidney injury (AKI) by modulating oxidized self-DNA-induced activation of the cGAS-STING pathway and NLRP3 inflammasome. These findings advance our mechanistic understanding of sterile inflammation in AKI and highlight new molecular targets for intervention.

• BAPTA-AM in Calcium-Dependent BDNF Release: Advanced Assay S

  2026-06-11

  Explore how BAPTA-AM, a leading cell-permeable calcium chelator, enables precision control of calcium-dependent BDNF localization and release in neuromuscular synapse formation. This article offers advanced assay guidance and unique mechanistic insights absent from standard protocol guides.

• Applied Workflows with (-)-Norepinephrine (+)-bitartrate

  2026-06-10

  (-)-Norepinephrine (+)-bitartrate from APExBIO enables reproducible modeling of adrenergic receptor signaling in cardiovascular and cardiomyopathy research. This guide delivers advanced experimental workflows, protocol optimization, and troubleshooting strategies that help translate bench findings into robust, high-impact outcomes.

• Octanoic Acid Nutrition Modulates Macrophage Polarization vi

  2026-06-10

  This study demonstrates that octanoic acid-rich enteral nutrition alleviates inflammatory bowel disease by shifting intestinal macrophage polarization through the PPARγ/STAT-1/STAT-6 pathway. The work clarifies mechanistic links between dietary fatty acids, nuclear receptor signaling, and immune balance, providing a framework for nutritional and pharmacological modulation of inflammation.

9211 records 2/615 page Previous Next 12345 下5页 Last page